Subscribe to Search results

The preliminary findings of the NBTS three-centre study showed that anti-HCV positivity indicated that a patient was suffering from non-A non-B Hepatitis, and that the test was detecting a viral marker associated with NANBH. The findings also included that, in general, 70-80% of patients suffering from treated (or severe) haemophilia were anti-HCV positive.

Published on:

A Spanish study reported that approximately 60% of recipients of anti-HCV positive donor blood would go on to develop NANBH.

Published on:

Dr Gunson concluded that the evidence suggested that routine anti-HCV tests would reduce the incidence of transfusion-transmitted NANBH, and should be implemented.

Published on:

Dr Gunson suggested that the routine use of a test for blood donations in the UK should not commence before an FDA licensing procedure was effected.

Published on:

Baroness Hooper wrote to Sir Robert McCrindle in relation to a letter he received from a constituent about Hepatitis C testing, and outlined the considerations that were examined in the decision on whether and when to introduce any new screening test.

Published on:

In an internal Department of Health minute from Dr David Kennedy to Dr Rejman, it was noted that the Chiron/Ortho test was under evaluation by the BTS and PHLS, and stated that another test, Fujiribo, was on the horizon.

Published on:

Dr Harris (Deputy Chief Medical Officer, England) sent a minute to various officials discussing the need for the establishment of a blood safety body to consider the transmission of infections like NANBH, and noted that the EAGA was not the appropriate body since it was only concerned with AIDS.

Published on:

The ACVSB working group on the further anti-HCV testing pilot met Department of Health officials and decided that an extended study of RIBA and PCR techniques for confirmatory testing might no longer be appropriate in light of an FDA decision.

Published on:

Dr Metters wrote a minute suggesting that the next ACVSB meeting should be brought forward to consider whether routine anti-HCV screening of blood donations should commence.

Published on:

Sir Robert McCrindle wrote to Virginia Bottomley attaching a complaint he had received from a constituent about the extensive resources being used for Hepatitis C testing.

Published on:

John Canavan circulated a first draft of a submission recommending the introduction of anti-HCV screening.

Published on:

Dr Charles Rizza wrote to all haemophilia centre directors and advised that Ortho were expected to supply test kits "for the non A non B marker, anti hepatitis virus C" to the PHLS in order to test several hundred people with haemophilia.

Published on:

Professor Tedder presented a paper on the development of a novel PCR-based assay that might provide another test in the future.

Published on:

In her oral evidence to the inquiry, Dame Contreras reflected that there was little good reason for delaying the start of testing - a policy of waiting when it had already been agreed to introduce a test was always going to result in unnecessary infections.

Published on:

In evidence, Dame Contreras told the Inquiry that arranging provision for counselling alongside anti-HCV testing was an issue of cost and manpower.

Published on:

Armour stated they would never have any prison plasma.

Published on:

Alpha's president stated that while Alpha had purchased some plasma collected from homosexuals for Hepatitis B Gamma and Vaccine, they had never used it to make AHF.

Published on:

Alpha's president stated that Alpha had no centre in San Francisco.

Published on:

Alpha's internal memo stated Alpha did not collect plasma from penal institutions.

Published on:

Alpha's US medical director's letter to US haemophilia centres stated they did not operate prison donor centres which had a large high risk population nor did they purchase plasma from prisons.

Published on: